Celgene Phase III Revlimid Data Show Survival Advantage In Multiple Myeloma Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial also showed longest median time to disease progression, 11.3 months, reported in previously treated MM patients in a Phase III study.